Market Overview

A Preview Of Collegium Pharmaceutical Q4 Earnings


Collegium Pharmaceutical, Inc. - Common Stock (NASDAQ: COLL) announces its next round of earnings Wednesday. Here is Benzinga's everything-that-matters guide for today's Q4 earnings announcement.

Earnings and Revenue

Sell-side analysts are expecting Collegium's loss per share to be near 57 cents on sales of $9.9 million.

Collegium's loss in the same period a year ago was $1.02. Quarterly sales came in at $1.3 million. If the company were to report inline earnings when it publishes results Wednesday, quarterly profit would be down 44.12 percent. Revenue would be have grown 658.25 percent from the same quarter last year.

Collegium's reported EPS has stacked up against analyst estimates in the past like this:


Quarter Q3 2017 Q2 2017 Q1 2017 Q4 2016
EPS Estimate -0.74 -0.83 -0.98 -1.07
EPS Actual -0.45 -0.72 -0.79 -1.02


Stock Performance

Over the last 52-week period, shares are up 74.47 percent. Given that these returns are generally positive, long-term shareholders can be content going into this earnings release.

Over the past 90 days, analysts have adjusted their estimates higher for EPS and revenues. The average rating by analysts on Collegium stock is a Buy. The strength of this rating has risen over the past 90 days.

Conference Call

Collegium Pharmaceutical's conference call is scheduled to begin at 4:30 p.m. ET and can be accessed here.

Posted-In: Earnings News Previews Trading Ideas


Related Articles (COLL)

View Comments and Join the Discussion!

Xenon Pharmaceuticals Q4 Earnings Outlook

A Value ETF That's Returned 785% During The Bull Market